Chicago ENT / Chicago Sleep Center accelerates patient outcomes, reduces overhead with EnsoSleep PPG
In 2024, Chicago ENT/Chicago Sleep Center (CENT/CSC) explored EnsoSleep PPG, an FDA-cleared, AI-powered sleep diagnostic SaMD that leverages data from pulse oximeters, to streamline the home testing process, reduce device costs, and expedite patient outcomes.
Since adding EnsoSleep PPG in August 2024, CENT/CSC has transitioned more than 75% of their home testing volume from flow-based to PPG-based devices, all in just 3 months. With the power of EnsoSleep PPG, CENT/CSC has been able to pivot to more affordable devices, reducing per device costs from $2,000 to $150.
Dive into the full case study to explore CENT/CSC’s rapid and efficient EnsoSleep PPG adoption and the significant benefits of adding affordable devices and cutting edge AI.